This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Biotech Investors: Mark Your 2005 Calendars

Abgenix (ABGX), Amgen (AMGN - Get Report): ABX-EGF, third-line colon cancer study, second half 2005;

Cypress BioScience (CYPB): Milnacipran, fibromyalgia phase III, third quarter 2005;

Genentech (DNA): Lucentis, age-related macular degeneration phase IIII, third quarter 2005. Avastin, front-line lung cancer phase III, second half 2005;

Allos Therapeutics (ALTH): Efaproxyn, brain metastases from lung cancer phase III, fourth quarter 2005;

Telik (TELK): Telcyta, ovarian non-small-cell lung cancer phase III, fourth quarter 2005;

Dendreon (DNDN): Provenge, prostate cancer phase III, second half/fourth quarter 2005;

Pharmacyclics (PCYC): Xcytrin, brain metastases from lung cancer phase III, second half 2005.

Northfield Laboratories (NFLD): Polyheme, blood substitute trauma phase III, year-end 2005;

CancerVax (CNVX): Canvaxin, melanoma phase III, end of 2005.

Turning the Page

On a calendar note of a personal sort, today marks my last day at

After four wonderful years here and 15 years as a business journalist, it's time for a new challenge. Next week, I'll be joining a New York-based investment firm as a biotech analyst (I'll remain on the West Coast.) I've been writing about biotech investing for a long time, so now's my chance to see if I can actually invest in biotech -- and make money doing it.

I'm excited to start the new gig, but I leave with some reluctance, because this has been (and continues to be) a great place to work and learn. I look back over the past four years and I marvel at how much I've learned about the way Wall Street really works. My investment education only accelerated when I was fortunate to join the staff of RealMoney two years ago.

Thanks to Jim Cramer, Dave Morrow, the entire cast of RealMoney contributors and all the writers and editors at TheStreet. It's been a great ride.

Finally, thanks to all my readers! Your constant feedback -- both naughty and nice -- kept me constantly energized and on my toes. I met some amazingly smart and friendly people through this Web site, readers who became trusted sources and helped me appear smarter than I am. I'm thankful and better for it, and will miss that part of the job more than anything.

Next week, I stop watching and start doing. I can't wait to get started. Thanks again, and continued success to all.
Adam Feuerstein writes regularly for In keeping with TSC's editorial policy, he doesn't own or short individual stocks, although he owns stock in He also doesn't invest in hedge funds or other private investment partnerships. He invites you to send your feedback to .
2 of 2

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free
IMCL $0.35 16.67%
AMGN $141.50 -1.60%
BIIB $245.70 -2.60%
CELG $99.72 -3.30%
AAPL $93.91 -0.38%


Chart of I:DJI
DOW 15,653.99 -260.75 -1.64%
S&P 500 1,823.07 -28.79 -1.55%
NASDAQ 4,244.7210 -38.8710 -0.91%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs